Michael Fiegl
- Hematology top 0.5%
- Acute Myeloid Leukemia Research 30
- Cancer Research top 1%
- Cancer Genomics and Diagnostics 14
- Oncology top 1%
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research 19
- Genomic variations and chromosomal abnormalities 11
- Immunology top 5%
- Immune Cell Function and Interaction 12
-
- Lymphoma Diagnosis and Treatment 20
-
- Lung Cancer Treatments and Mutations 19
- Lung Cancer Diagnosis and Treatment 15
- Co-authors
- Michael AndreeffIsmael SamudioAlexandar TzankovWolfgang HilbeJohannes DrachWilliam SterlacciH. DenzHerbert Jamnig
- Cited by
- HematologyCancer ResearchOncology
- Partner nations
- AustriaGermanySwitzerland
In The Last Decade
Michael Fiegl
163 papers receiving 5.8k citations
Hit Papers
Peers
Comparison fields: 5 of 140
- Hematology 1.3k
- Cancer Research 1.1k
- Oncology 1.9k
- Genetics 559
- Immunology 841
Countries citing papers authored by Michael Fiegl
This map shows the geographic impact of Michael Fiegl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Fiegl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Fiegl more than expected).
Fields of papers citing papers by Michael Fiegl
This network shows the impact of papers produced by Michael Fiegl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Fiegl. The network helps show where Michael Fiegl may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Michael Fiegl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2021 | 4 | |
| 3 | 2018 | 5 | |
| 4 | Persistence of Driver Mutations during Complete Remission Associates with Shorter Survival and Contributes to the Inferior Outcomes of Elderly Patients with Acute Myeloid Leukemia | 2016 | 2 |
| 5 | 2014 | 10 | |
| 6 | 2014 | 11 | |
| 7 | 2014 | 6 | |
| 8 | 2013 | 12 | |
| 9 | 2012 | 26 | |
| 10 | 2011 | 65 | |
| 11 | 2011 | 7 | |
| 12 | 2011 | 35 | |
| 13 | 2010 | 22 | |
| 14 | 2008 | 136 | |
| 15 | 2007 | 11 | |
| 16 | 2006 | 34 | |
| 17 | 2005 | 7 | |
| 18 | 2004 | 28 | |
| 19 | 2000 | 28 | |
| 20 | 1999 | 7 |
About Michael Fiegl
Michael Fiegl is a scholar working on Hematology, Genetics and Oncology, having authored 165 papers that have together received 5.9k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (30 papers), Lymphoma Diagnosis and Treatment (20 papers), Chronic Lymphocytic Leukemia Research (19 papers), Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Diagnosis and Treatment (15 papers), Cancer Genomics and Diagnostics (14 papers), Immune Cell Function and Interaction (12 papers) and Genomic variations and chromosomal abnormalities (11 papers). The work is most often cited by research in Hematology (1.3k citations), Cancer Research (1.1k citations) and Oncology (1.9k citations). Michael Fiegl has collaborated with scholars based in Austria, Germany and Switzerland. Frequent co-authors include Michael Andreeff, Ismael Samudio, Alexandar Tzankov, Wolfgang Hilbe, Johannes Drach, William Sterlacci, H. Denz, Herbert Jamnig, Niklas Zojer and Marina Konopleva.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.